Perspective reports updated Phase 1/2a data for [212Pb]VMT-α-NET at ESMO 2026

Perspective Therapeutics, Inc. announced updated interim results on October 23, 2026 from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET (bamzireotide navoxetan) in patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors. The data were presented as a rapid oral presentation at the European Society for Medical Oncology Congress 2026, held October 23-27, 2026 in Madrid, Spain.¹

In the trial, the objective response rate, including unconfirmed responses, was 33% in Cohort 2 (5.0 mCi, n=46) and 50% in Cohort 3 (6.0 mCi, n=20, as of September 10, 2026).¹ Disease control rate was 89% and 95% in Cohorts 2 and 3, respectively, and progression-free survival was 72% at 18 months across all cohorts.¹ PFS rates were 86% at six months and 74% at 12 months across Cohorts 1, 2, and 3.¹

On safety, no dose-limiting toxicities, Grade 4 or 5 treatment-emergent adverse events, or adverse event-related treatment discontinuations were reported.¹ A low incidence of high-grade TEAEs, 20 of 68 patients or 29%, was observed, all of which were Grade 3.¹ Two patients, or 2.9%, had Grade 3 renal events, with renal function continuing to be characterized over longer follow-up.¹

The ESMO presentation was based on an analysis of 68 patients across three dose cohorts, with a data cut-off date of September 2, 2026, approximately 20 weeks after the ASCO 2026 data cut-off.¹

Looking ahead, the company said it aims to complete Phase 3 site start-up preparations around year-end 2026, positioning it to rapidly activate clinical sites following an End-of-Phase 2 meeting with the FDA, with Phase 3 initiation expected in 2027.¹ Additional data are planned for presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium on November 5, 2026, and the EORTC-NCI-AACR Symposium on November 20, 2026.¹